Johnson & Johnson $JNJ Shares Acquired by Strengthening Families & Communities LLC

Strengthening Families & Communities LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 1,030.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,955 shares of the company’s stock after buying an additional 20,924 shares during the quarter. Johnson & Johnson accounts for approximately 0.9% of Strengthening Families & Communities LLC’s holdings, making the stock its 22nd biggest holding. Strengthening Families & Communities LLC’s holdings in Johnson & Johnson were worth $4,211,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. United Bank boosted its holdings in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the period. Sivia Capital Partners LLC grew its position in shares of Johnson & Johnson by 13.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after buying an additional 692 shares during the last quarter. Wealth Group Ltd. raised its stake in Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares during the period. Finally, Merit Financial Group LLC lifted its holdings in Johnson & Johnson by 30.8% in the second quarter. Merit Financial Group LLC now owns 179,717 shares of the company’s stock worth $27,452,000 after acquiring an additional 42,294 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst upgrades and raised price targets are boosting investor sentiment — Bank of America raised its PT to $227 (from $221) and RBC raised its PT to $255 while keeping an Outperform rating, signaling confidence in JNJ’s outlook. BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here’s Why RBC Raises Price Target on Johnson & Johnson to $255
• Positive Sentiment: Clinical and commercial oncology updates are underpinning the longer‑term earnings thesis — recent ERLEADA and DARZALEX FASPRO data/updates are framed as material to JNJ’s oncology growth, and commentary expects oncology sales to roughly double over time. That bolsters the case for faster revenue/earnings ramp. ERLEADA And DARZALEX FASPRO Updates Shape Johnson And Johnson Oncology Story Johnson & Johnson’s Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?
• Positive Sentiment: Product and medtech momentum: JNJ MedTech announced Varipulse updates and a new ultrasound catheter, and ACUVUE launched a novel daily multifocal toric contact lens in the UK/Ireland — both moves expand near‑term commercial catalysts and diversify growth drivers outside pharma. Johnson & Johnson MedTech announces updates to Varipulse, new ultrasound catheter Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens
• Neutral Sentiment: Context piece: recent analysis highlights JNJ’s ~50% stock rally over the past nine months driven by improved earnings, product wins and legal progress — useful for sentiment context but not new company-specific catalyst. What’s Behind The 50% Surge In JNJ Stock?

Analysts Set New Price Targets

Several equities analysts have recently commented on JNJ shares. Citigroup upped their target price on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Guggenheim increased their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Price Performance

Shares of JNJ opened at $234.26 on Thursday. Johnson & Johnson has a one year low of $141.50 and a one year high of $235.83. The stock’s fifty day moving average is $212.27 and its 200-day moving average is $193.02. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $564.40 billion, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The firm had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. During the same quarter in the prior year, the firm posted $2.04 EPS. Johnson & Johnson’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.